Skip to main content
. 2019 Jan 23;155(3):342–346. doi: 10.1001/jamadermatol.2018.5077

Figure 1. Clinical Response to Janus Kinase Inhibition in Familial Chilblain Lupus.

Figure 1.

A, Mean (SD) revised cutaneous lupus area and severity index (R-CLASI) activity during treatment. B, Pain assessed by the visual analog scale (VAS) (where 0 indicates no pain and 10 indicates most severe pain). C, Mean (SD) type I interferon (IFN) score in blood before and after 3 months of baricitinib treatment measured by quantitative reverse transcription–polymerase chain reaction of IFN-stimulated genes (ISGs). aSpearman ρ = –0.7970; P < .001. bSpearman ρ = –0.9550; P < .001. cSpearman ρ = –0.9260; P < .001.